Teva wins UK appeal on Copaxone

The Court of Appeal has ruled that Copaxone patents in the UK are valid through May 2015.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has chalked up a victory in the UK against Mylan Inc. (NYSE: MYL), after losing a court case in the US. The Court of Appeal for England and Wales has found in favor of Teva, upholding the validity of the asserted claims of its Copaxone patent through May 2015. The court dismissed the appeal by Mylan subsidiary Generics [UK] Ltd.

Copaxone, for the treatment of multiple sclerosis, is Teva's flagship product, and is reportedly responsible for half of the company's profits. On Friday, the US Court of Appeals for the Federal Circuit ruled in favor of Mylan and Sandoz Inc. that Copaxone's patents were only valid until May 2014. That ruling will allow the launch of generic Copaxone in the US next year. Teva's share price fell 2% in New York yesterday, and fell 2.5% in morning trading on the TASE today.

“This decision upholding the patent strengthens Teva’s exclusivity of Copaxone in the UK until at least the date of the patent expiry," said Teva president and CEO Dr. Jeremy Levin. Thousands of patients in the UK and elsewhere depend on Copaxone for relief in relapsing-remitting multiple sclerosis, and we are pleased that the English Court of Appeal has upheld the validity of the patent until its expiry in 2015."

Teva intends to appeal against the US appellate court decision, arguing that any generic version of Copaxone should undergo full clinical trials in order to obtain US Food and Drug Administration (FDA) approval, because of the complexity of the formula. Such trials would take years, and delay competition to Copaxone, and would also give Teva time to switch more patients to the Copaxone 40 mg dosage, which is under development and due for launch in early 2014. This dosage requires three weekly injections, instead of the daily injections for the current treatment. The new version has patent protection through 2030. Teva expects to obtain FDA approval for Copaxone 40 mg dosage in early 2014.

Teva today reiterated its statement following the US appellate court ruling, saying, "Given the complexity of Copaxone, unpredictable differences between a proposed generic product and Copaxone could lead to immunogenic effects in patients. The inability to fully characterize the active ingredients of the product leads many experts to believe that the only way to ensure the safety, efficacy and immunogenicity of any purported generic version of Copaxone would be through full-scale, placebo-controlled clinical trials with measured clinical endpoints (such as relapse rate) in relapsing-remitting multiple sclerosis patients."

Published by Globes [online], Israel business news - www.globes-online.com - on July 30, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Itamar Ben-Gvir  credit: Noam Moskowitz, Knesset Spokesperson's Office Otzma Yehudit rejoins government

Itamar Ben-Gvir's party left the government in January in protest against the ceasefire in Gaza. The resumption of fighting has paved its way back.

Wiz founders Yinon Costica, Assaf Rappaport, Ami Luttwak, Roy Reznik credit: Avishag Shaar Yishuv Israel's biggest ever exit: Google buying Wiz for $32b

Google has confirmed that an agreement has been signed for an all-cash deal. Wiz will remain an independent company under Google.

Bezhalel Machlis  credit: Assaf Shilo/Israel Sun Elbit Systems CEO: Our potential in Europe is huge

Bezhalel Machlis was speaking at an investor conference after the company released 2024 results showing revenue up 14.3%.

Gaza Strip, March 17 2025  credit: Reuters/Anadolu IDF resumes assault on Hamas

Extensive aerial attacks were carried out against targets in the Gaza Strip overnight.

Wiz founders Yinon Costica, Assaf Rappaport, Ami Luttwak, Roy Reznik credit: Avishag Shaar Yishuv Google renews attempt to buy Wiz - report

According to "The Wall Street Journal", Google parent company Alphabet is negotiating to buy the Israeli cloud computing security company for $30 billion.

Orit Strook  credit: Marc Israel Sellem/The Jerusalem Post Finance C'ttee approves NIS 300m coalition funds distribution

The money will mainly go to Religious Zionist party minister Orit Strook's Ministry of Settlements and National Missions.

Dangoor Academy  credit: British Embassy in Tel Aviv British Embassy showcases Israeli healthcare startups

The nine startups participated in the Dangoor HealthTech Academy, a program that connects Israeli startups with the UK healthcare system.

NextVision Stabilized Systems  credit: Shlomi Yosef/Tali Bogdanovsky Next Vision shareholders make NIS 230m exit

A British hedge fund has bought a 2.5% stake in the stabilized cameras company.

Energean CEO Mathios Rigas at the Israel Business Conference   credit: Shlomi Yosef Energean's $1b gas fields sale at risk

The sale of the energy company's asset portfolio in Egypt, Italy and Croatia may fall through because of the buyer's difficulties with the Italian regulator.

Kela Technologies founders Jason Manne, Hamutal Meridor, Alon Dror and Omer Bar Ilan  credit:  Yosef Haim Alterman Defense tech co Kela raises $39m

In response to the events of October 7, Kela has developed a platform for rapid integration of commercial technologies into military systems.

Benjamin Netanyahu  credit: ‎Alex Kolomoisky, Yediot Aharonot Firing the Shin Bet chief: The hurdles

Prime Minister Benjamin Netanyahu says he has "lost trust" in Shin Bet head Ronen Bar. Will this be enough to overcome legal challenges to his dismissal?

Emiliano Calemzuk  credit: PR CEO and "investor group" buying out Reshet 13

CEO Emiliano Calemzuk and the other investors will hold 74% of the television channel, while Len Blavatnik’s Access Industries and WBD will remain with 26%.

Inflation  credit: Tali Bogdanovsky Unexpectedly low February CPI reading cuts inflation

While inflation in Israel in the 12 months to the end of February 2025 is lower than forecast, housing prices continue to rise.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Competition Authority allows Delek takeover of Isracard

The Competition Authority is considered the easier of the two regulatory hurdles that the deal must overcome, the other being the Supervisor of Banks.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018